{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-023441","form_type":"8-K","ticker":"ENVB","cik":"0000890821","company_name":"Enveric Biosciences, Inc.","filed_at":"2025-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.509171+00:00","generated_at":"2026-05-16T20:03:18.112136+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Enveric Biosciences Q3 net loss $3.4M, cash $3.8M; EB-003 advances toward IND 2026","bullets":["Net loss of $3.4M ($10.81 per share) in Q3 2025 vs $2.1M ($43.10) in Q3 2024; cash $3.8M as of Sept 30, 2025.","Lead candidate EB-003: completed pre-IND dose range studies, positive PTSD data, FDA pre-IND response; IND planned 2026.","Hired Fish & Richardson to defend U.S. Patent 12,138,276 against Gilgamesh PGR; patent covers Bretisilocin (AbbVie, $1.2B).","Completed reverse stock split 1:12 on Oct 28, 2025 after Nasdaq bid price deficiency delisting determination.","Gross proceeds of ~$2.2M from warrant exercise; $7.9M net raised in first nine months of 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-023441","json":"https://secwatch.observer/filing/0001493152-25-023441.json","markdown":"https://secwatch.observer/filing/0001493152-25-023441.md","text":"https://secwatch.observer/filing/0001493152-25-023441.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/890821/000149315225023441/0001493152-25-023441-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/890821/000149315225023441/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:03:18.112136+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}